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ABSTRACT

Possible pathologic effect of HMGB1 on P. gingivalis induced inflammatory
response by macrophages.
DEGREE DATE: July 2019
MICHELLE M. TORRES SANTOS, D.M.D.
COLLEGE OF DENTAL MEDICINE NOVA SOUTHEASTERN UNIVERSITY
Thesis Directed by:
•

Toshihisa Kawai, D.D.S., Ph.D. (Mentor)

•

Alexandru Movila, Ph.D. (Committee Member)

•

Umadevi Kandalam, Ph.D. (Committee Member)

•

Maria Hernandez, D.D.S. (Committee Member)

BACKGROUND: Periodontitis is an inflammatory disease caused by poly-microbial
infection that leads to destruction of connective tissue and alveolar bone. It is
well documented that bacteria-derived virulent factors that can act on Toll-like
receptors (TLRs), represented by Lipopolysaccharides (LPS), are engaged in the
initiation of inflammatory responses. However, while LPS is also produced by the
bacteria colonized in the healthy periodontal tissue, inflammation is not induced
by LPS in those periodontal healthy subjects, suggesting the requirement of
additional factor to upregulate the LPS-mediated inflammatory response in
periodontal tissue. Recent studies revealed that novel class of endogenous
proinflammatory mediator, high mobility group box 1 (HMGB1) protein, can be
released extracellularly from host cells in response to a variety of stimuli, such as
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pathogen invasion. Although, significantly elevated levels of HMGB1 are reported
in gingival tissues and gingival crevicular fluid (GCF) of chronic periodontitis
patients, its pathophysiological role in periodontitis is not clear. The herein study
investigated the effects of HMGB1 on P. gingivalis-LPS (Pg-LPS)-elicited
inflammation induced in macrophages using an in vitro assay system.
OBJECTIVE: The present study examined the effects of the novel host danger
alarming molecule, high mobility group box 1 (HMGB1), on pro-inflammatory
cytokine production by P. gingivalis-LPS (Pg-LPS)-stimulated macrophages.
HYPOTHESIS: We hypothesized that HMGB1 forms complex with Pg LPS which
can induce hyper inflammatory response by macrophages. HMGB1-Pg-LPS
complex is expected to induce production of more pro-inflammatory cytokines
(i.e. Tumor Necrosis Factor alpha (TNF-a) and Interleukin 6 (IL-6)) than those
induced by LPS or HMGB1 alone.
MATERIALS AND METHODS: RAW264.7 macrophage cells (ATCC) were stimulated
in vitro for 24 hours with HMGB1, P. gingivalis-LPS, E. coli-LPS or HMGB1 in a
preformed complex with P. gingivalis-LPS or E. coli-LPS. Supernatants were
collected and kept at -20°C until analysis. Chemical antagonists for TLR4, TLR2
and RAGE were applied to some cultures in the presence or absence of LPS
and/or HMGB1. TNF-a and IL-6 levels in the culture supernatants were
measured by enzyme-linked immunosorbent assay (ELISA). PAMP receptor
genes analysis was performed to assess TLR2, TLR4 and RAGE mRNAs
expressed in RAW264.7 cells by quantitative PCR technique. The levels of

viii

macrophage (RAW264.7) proliferations in response to stimulation to LPS with or
without HMGB1 was determined by WST assay.
RESULTS: Compared to E.coli-LPS that induced prominently elevated TNF-a
production by RAW264.7 macrophages, Pg-LPS as well as HMGB1 showed
significantly lower levels of TNF-a production. However, combination of HMGB1
with Pg-LPS, but not E.coli-LPS, showed a remarkable additive effect on TNF-a
production by RAW264.7-macrophages which was abrogated by addition of
TLR4-antagonist. Interestingly, additive effect was only found on production of
TNF-a, but not IL-6. HMGB1-Pg-LPS complex also increased the proliferation of
macrophages, whereas HMGB1-E.coli-LPS complex did not affect the
proliferation of macrophages. According to the qPCR-based analysis of gene
expressions for PAMP receptors, the macrophages used in this study expressed
mRNAs for TLR2, TLR4 and RAGE as putative ligands for HMGB1. Pg-LPS
alone or in combination with HMGB1 did not change the expression levels of all
three PAMPs expressed by macrophages, indicating that elevated production of
TNF-a by HMGB1-Pg-LPS complex was not mediated by modulation of PAMP
receptors expressed on macrophages.
CONCLUSION: These results demonstrated that HMGB1 can form a hyperinflammatory complex with Pg-LPS, but not E. coli-LPS, that activates TLR4 and
promotes TNF-a production from the macrophages, suggesting that locally
released HMGB1 may up-regulate the pathogenic engagement of keystone
pathogen, P. gingivalis, in periodontitis.
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CHAPTER 1: INTRODUCTION
1.1

BACKGROUND

1.1.1 Bacterial pathogen associated molecular patterns (PAMPs)
Bacterial pathogen associated molecular patterns (PAMPs) are produced
by bacteria from the plaque of periodontitis as well as periodontally healthy
plaque.1 The current consensus of periodontitis pathogenesis supports that
PAMPs, such as LPS by bacteria, play a key role in induction of inflammation by
binding to Toll like receptors (TLRs) expressed on the host innate immune cells.2
However, LPS is also produced by bacteria present in the periodontal plaque of
healthy subjects in which does not induce inflammation.1 While consensus
supports that the theory of endotoxin-tolerance may account for the healthy
subject’s unresponsiveness to LPS, it remains elusive how periodontal
inflammation of patients with periodontitis is induced in the state of previously
acquired endotoxin-tolerance.3 It is plausible that, besides PAMPs, there may be
additional factor or mechanism that modulate the inflammatory responses elicited
by bacterial challenge in periodontitis.

1.1.2 HMGB1 - an endogenous damage-associated molecular patterns (DAMPs)
HMGB1, an endogenous damage-associated molecular patterns
(DAMPs), forms hyper inflammatory complex with PAMPs. High mobility group
box 1 (HMGB1) protein was originally discovered as a nuclear factor that plays a
relevant role in regulation of transcription by binding DNA and transcription
factors. Therefore, it was believed that HMGB1 only exists within the nucleus to
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act as a nuclear DNA chaperone exerting vital functions. However, emerging
studies revealed that extracellularly released HMGB1 functions as a proinflammatory factor and that it is correlated with multiple inflammatory and
autoimmune diseases.4,5 When tissue injury is inflicted, HMGB1 can be released
extracellularly conveying several inflammatory functions.6 Based on its nature
released from endogenous cells in response of tissue injury, HMGB1 belongs to
DAMPs, also known as alarmins. HMGB1 can be actively secreted into the
extracellular space by activated monocytes and macrophages, or passively
released from the nuclei of necrotic or damaged cells. Extracellularly released
HMGB1 binds Receptor for Advanced Glycation End-products (RAGE) to elicit
the inflammatory signal which, in turn, lead to the production of proinflammatory
factors.7,8 Very importantly, HMGB1 forms a hyper inflammatory complex with
bacterial LPS or IL-1 and stimulates inflammation by binding with TLR2, TLR4
and IL-1R. For example, it is reported that stimulation with preformed HMGB1LPS complexes induces a 100-fold stronger response than stimulation with
comparable levels of LPS alone. Thus, HMGB1 acts as a key pro-inflammatory
factor and late-acting distal inflammatory mediator during cell injury necrosis and
inflammation.9 Compared with other pro-inflammatory cytokines, the release of
HMGB1 is retarded for several hours and it can be promoted by IL-1b and
TNF-a. Subsequently, extracellular HMGB1 convey a positive feedback loop by
activating the monocytes to stimulate further release of pro-inflammation
cytokines.10
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Figure 1: Extracellular HMGB1’s property to adhere PAMPs. HMGB1 is a dynamic
protein composed of three domains. Positively charged domain A/B binds to
negatively charged DNA and LPS. Negatively charged receptor binding domain
facilitates its ligation to HMGB1 receptors

1.1.5

Extracellularly released HMGB1 in Periodontal Diseases

The level of extracellularly released HMGB1 are elevated in
periodontitis.11 In the oral cavity, lipopolysaccharide (LPS) of major periodontal
pathogens, such as Porphyromonas gingivalis (Pg), induces HMGB1 secretion
from human gingival fibroblasts which might contribute to periodontal tissue
destruction.3,10,12 Significantly elevated levels of HMGB1 are reported in gingival
tissues and GCF of chronic periodontitis patient, as compared to periodontally
healthy patients.12,13 Expression of HMGB1 in peri-implant crevicular fluid (PICF)
is also elevated in the patients with peri-implantitis.9 Elucidating HMGB1 receptor
usage in processes where HMGB1 acts alone or in complex with other molecules
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in the context of periodontitis is essential for the understanding of basic HMGB1
biology and for designing HMGB1-targeted therapies.
1.1.4 Porphyromonas gingivalis – Microbiology and Pathogenesis
It was originally reported that P. gingivalis LPS can bind with TLR2, unlike
to other Gram negative bacterial LPS that bind with TLR4. However, later studies
revealed that Pg-LPS activates cells through binding with TLR4, but not TLR2.
The contaminant lipoprotein in Pg-LPS samples was attributed to the previously
reported Pg-LPS’ activity to stimulate TLR2.14 It is thought that pathogenesis of
periodontitis is elicited by “dysbiosis of microbiome” in periodontal plaque
resulting from the diminished number of beneficial symbionts and inversely
increased number of pathogens, such as P. gingivalis, a Gram-negative
anaerobe, possesses unique feature compared to the other Gram-negative
bacteria.15,16 Especially, LPS derived from P. gingivalis has been shown to differ
from LPS produced by other Gram-negative bacteria in structure and function.16
The number of P. gingivalis identified in the dental plaque of periodontal pocket is
proportional to the levels of pro-inflammatory cytokines detected in gingival
crevice fluid (GCF), indicating that unique virulent factor produced by P.
gingivalis is engaged in the induction and/or upregulation of inflammatory
response in periodontitis.1,2 However, the virulent factor produced by P. gingivalis
that is responsible for the upregulation of pro-inflammatory cytokine production in
periodontitis remains elusive.
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1.1.5 HMGB1 and P. gingivalis-LPS
In terms of unique property of HMGB1 that forms hyper reactive complex
with LPS and other bacterial PAMPs,17 it is not known whether P. gingivalis LPS
can form a complex with HMGB1 and if such HMGB1-Pg-LPS complex
upregulates the inflammatory signal as a result of ligation with, TLR4, TLR2 or
RAGE. The possible role and mechanisms by which HMGB1 is involved in
regulating inflammatory response of periodontitis in association with P. gingivalis
infection is largely unknown. This is the first study to compare the difference
between P. gingivalis LPS-HMGB1 complex and E. coli LPS-HMGB1 complex in
induction of inflammatory response by innate immune macrophages. Findings
from this investigation not only elucidated the basic pathophysiology of HMGB1
as a pro-inflammatory promoter for bacterial PAMPs, but also identified the
molecular target to design a novel therapeutic approach for periodontitis.

1.2

CURRENT STUDY

1.2.1 Purpose
Since periodontitis not only deteriorates the patient’s quality of life, but
also increases the risk for chronic systemic diseases, there is a strong need for
developing novel preventive and therapeutic approaches for this disease.
Therefore, the present study that challenges to elucidate the pathogenesis of
periodontitis has translational significance.
The current consensus of periodontal pathogenesis supports that
pathogen associated molecular patterns (PAMPs), such as LPS released from
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bacteria, play a key role in induction of inflammation by binding to Toll like
receptors (TLRs) expressed on the host innate immune cells. However, LPS is
produced by bacteria present in the periodontal plaque of healthy subjects which
don’t induce inflammation, indicating that there may be additional factors that
modulate the inflammatory responses elicited by bacterial challenge in
periodontitis. To this end, the purpose of the present study was to investigate the
role of danger associated molecular pattern (DAMPs), especially, HMGB1, as a
TLR-signal modulatory factor, by forming a hyper inflammatory complex with
PAMPs. It is plausible that the proposed study may elucidate the molecular
mechanism that can’t be explained by simple PAMPs-TLR inflammation axis,
possibly leading to the paradigm-shift in the research of periodontal
pathogenesis.
1.2.2 Hypothesis
We hypothesized that HMGB1 forms complex with Pg LPS which can
induce hyper inflammatory response by macrophages. HMGB1-Pg-LPS complex
is expected to induce production of more pro-inflammatory cytokines (i.e. Tumor
Necrosis Factor alpha (TNF-a) and Interleukin 6 (IL-6)) than those induced by
LPS or HMGB1 alone
1.2.3 Specific Aims
To address the above noted hypothesis, the specific aims of this study is
to understand the possible effects of HMGB1, a danger associated molecular
pattern (DAMP), on the P. gingivalis LPS-induced inflammatory response by
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macrophages. We were in particular interested to compare the magnitude of
inflammation induced by complex between HMGB1 and P. gingivalis LPS,
compared to that between HMGB1 and E. coli LPS. We also challenged to
identify the receptors that are responsible for binding the Pg-LPS/HMGB1
complex.

Specific Objectives:
Specific Aim 1: To assess the production pattern of pro-inflammatory cytokines
(TNF-a, IL-6) by a mouse macrophage cell line (RAW264.7) in
response to the stimulation with P. gingivalis LPS or E. coli LPS
in the presence or absence of recombinant HMGB1. The
expressions of PAMP receptors (TLR2, TLR4, and RAGE)
mRNA and levels of the aforementioned cytokines (TNF-a, IL-6)
were monitored using qPCR and ELISA.

Specific Aim 2: To determine the receptor which is responsible for the ligation of
HMGB1/Pg-LPS complex and to induce inflammatory signal.
RAW264.7 cells were stimulated with HMGB1/Pg-LPS complex
in the presence or absence of chemical antagonist of TLR2,
TLR4, and RAGE, and the expression patterns of TNF-a were
compared using ELISA.
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CHAPTER 2: MATERIALS AND METHODS
2.1

SAMPLING PLAN

2.1.1 Sample Size
For a power of 0.8 and alpha of 0.05, experiments of cell culture and
sampling were performed using triplicate wells or more for each treatment. As a
typical example of data collected from TNF-a produced by mouse macrophage
cell line (RAW264.7 – 104 cells/well) stimulated with or without LPS, average ±
SD for no stimulation is 1.0±0.17 ng/ml, while that of LPS-stimulated group is
1.4±0.17. Based on the power calculation, n=3/group was required.

2.2

INSTRUMENTATION

2.2.1 Dependent Variables
Cytokine analysis: TNF-a and IL-6 (ng/mL) levels in the culture supernatants
were measured by enzyme-linked immunosorbent assay
(ELISA).
Gene Expression: Quantitative PCR were conducted to measure TLR2, TLR4
and RAGE genes (relative ratio compared to GAPDH).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
served as internal control.
2.2.2 Independent Variables
Inhibitors for TLR4, TLR2 and RAGE (10, 100 ng/ml, respectively) were applied
to some cultures in the presence or absence of P. gingivalis LPS alone, E. coli
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LPS alone, HMGB1 alone, E. coli LPS-HMGB1 complex, and P. gingivalis LPSHMGB1 complex.
2.2.3 Levels of Measurements
Variables were quantitative and continuous. RAW264.7 macrophages cells were
stimulated with HMGB1 and the effects on cytokine production and mRNA
expressions were evaluated using ELISA and quantitative Polymerase Chain
Reaction (PCR), respectively.
Reliability and Validity: All experiments were performed in a triplicate fashion and
repeated at least twice to confirm the reproducibility.
2.3

STUDY DESIGN

2.3.1 Overall Experiment Design
RAW264.7 macrophage cells (ATCC) were plated at 100,000 cells per
well in a 96-well plate in culture medium (DMEM medium supplemented with
10% FBS, penicillin, streptomycin, HEPES, sodium pyruvate and bmercaptoethanol). Cells were then stimulated for 24 hours with HMGB1, P.
gingivalis LPS, E. coli LPS or HMGB1 in a preformed complex with P. gingivalis
LPS or E. coli LPS under standard culture conditions. Supernatants were
collected to perform various analyses. Proinflammatory cytokines, TNF-a and IL6, levels in the culture supernatants were measured by ELISA. The levels of
macrophage (RAW264.7) proliferations in response to stimulation with LPS in the
presence or absence of HMGB1 was determined by WST assay. PAMP receptor
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genes analysis of TLR2, TLR4 and RAGE mRNAs expressed in RAW264.7 cell
culture were measured by quantitative PCR technique.
The second purpose of the experiment was to determine the receptor(s)
engaged in the recognition of complex generated between HMGB1 and E. coliLPS, or Pg-LPS. To this end, chemical antagonists for TLR4, TLR2 and RAGE
(10, 100 ng/ml, respectively) were applied to the RAW264.7 cell cultures in the
presence or absence of Pg-LPS and/or HMGB1. After stimulation for 24 hours,
TNF-a levels in the culture supernatants were measured by ELISA.

Figure 2: Overall Experiment Design
2.3.2 Reagents
Tag-free recombinant rat HMGB1 (free of endotoxin) was purchased from
Creative Biomart (Shirley, NY, 99% homology to human and mouse HMGB1).
Dulbecco’s modified Eagle’s medium (DMEM), phosphate-buffered saline (PBS),
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penicillin, streptomycin, 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
(HEPES), sodium pyruvate and d b-mercaptoethanol were from Invitrogen
(Carlsbad, CA, USA). Highly purified LPS extracted from Escherichia coli O55:B5
and P. gingivalis were also purchased from Invivogen (San Diego, CA, USA).
Chemical antagonists for TLR4, TLR2 and RAGE, i.e., Resatorvid (TAK-242),
3,4,6-Trihydroxy-2-methoxy-5-oxo-5H-benzocycloheptene-8-carboxylic acid
hexyl ester (CU-CPT22) and N-Benzyl-4-chloro-N-cyclohexylbenzamide (FPSZM1), respectively, were purchased from Calbiochem.
2.3.3 Culture of Macrophages
RAW264.7 mouse macrophage cells (ATCC) were plated at 100,000 cells
per well in a 96-well plate in DMEM medium supplemented with 10% FBS,
penicillin, streptomycin, 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid
(HEPES), sodium pyruvate and b-mercaptoethanol. Cells were then stimulated
for 24 hours with HMGB1, P. gingivalis LPS, E. coli LPS or HMGB1 in a
preformed complex with P. gingivalis LPS or E. coli LPS. Supernatants were
collected and kept at -20°C until analysis. Chemical antagonists for TLR4, TLR2
and RAGE (10, 100 ng/ml, respectively) were applied to some cultures in the
presence or absence of LPS and/or HMGB1.
2.3.4 Preparation of HMGB1 Complexes
HMGB1 in PBS were mixed together with E. coli LPS or P. gingivalis LPS
in polypropylene tubes in different ratios to give final concentrations in cell
cultures. The stimulatory ability of the complexes depends on both the
11

temperature and the length of time in which they are formed. For this study, the
mixtures were incubated at room temperature (25°C) for 10 minutes before
addition to the cell culture, following the protocol published by another group.18,19
2.3.5 Cytokine Analysis
TNF-a and IL-6 levels in the culture supernatants were measured by
enzyme-linked immunosorbent assay (ELISA) using DuoSet kits from R&D
Systems (Minneapolis, MN, USA) and following the manufacturer’s instructions.
Mouse HMGB1 ELISA kit were purchased from LifeSpan BioScience inc (Seattle,
WA, USA).
2.3.6 Polymerase Chain Reaction (PCR)
mRNAs for TLR2, TLR4 and RAGE expressed in RAW264.7 cells were
measured by quantitative PCR technique. Total RNA was isolated from cells
using RNA-Bee isolation reagent (AMS Biotechnology, Cambridge, MA, USA),
following the manufacturer’s instructions, and subjected to reverse transcription
with the Verso cDNA synthesis kit (Thermo Fisher, Waltham, MA, USA) in the
presence of random primers and oligo-dT. Gene expression was quantified using
the LightCycler ® 480 SYBR Green I Master (Roche Diagnostics, Indianapolis,
IN, USA). The list of Primer (Taqman, Applied Biosystems inc):
Ø mouse TLR2; Mm01213946_g1 Tlr2
Ø mouse TLR4; Mm00445273_m1 Tlr4
Ø mouse RAGE; Mm01134790_g1 Ager
Ø Control GAPDH; Mm 99999915 g1 Gapdh
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2.3.7 WST PROLIFERATION ASSAY
Following the culture method described above, RAW264.7 cells were
incubated in a 96 well plate (100,000 cells/200 ul/well) with test compounds (LPS
or HMGB1) for 24 hours. After the incubation, 100 ul of culture supernatant was
removed and the final volume of culture medium in each well was adjusted to
100 µl. Then, Cell Proliferation Reagent WST-1 (10 ul/well, Millipore Sigma) was
added to each well of 96-well plate. The plates were incubated at 37°C for 2
hours. The developed color in each well of the plate was measured for the
absorbance at optical density (OD) 450 nm using a plate reader (Synergy H1,
Biotek).
2.4

STATISTICAL ANALYSIS
The proposed in vitro experiments were performed in a triplicate fashion

and repeated at least twice to confirm the reproducibility. Descriptive statistics
were calculated for all study variables. This includes the mean and standard
deviation (SD) for continuous measures, counts and percentages for categorical
variables. A Welch, two-samples t-test, was used to compare means between
the control and experimental groups. To look for differences between more than
two groups, a general linear model (ANOVA) with robust standard errors was
used. Tukey’s HSD test was employed for all post-hoc comparisons. The
statistical package R 3.2.2 was used to create and test the ANOVA models.
Statistical significance is found at p < 0.05.
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CHAPTER 3: RESULTS
3.1.

PRO-INFLAMMATORY CYTOKINES ANALYSIS: ELISA
The inflammatory responses of all five groups were assessed by

measuring the levels of proinflammatory cytokines produced by macrophage
(RAW 264.7) cells. Supernatants collected from the RAW 264.7 cells stimulated
with or without LPS and/or HMGB1 for 24 hours were subject to commercially
available enzyme-linked immunosorbent assay (ELISA) for TNF-a and IL-6.
Results from measuring TNF-a levels showed that E. coli-LPS either alone or in
combination with HMGB1 complex induced prominently elevated TNF-a
production compared to the stimulation with HMGB1 alone. Although addition of
HMGB1 to all three concentrations of LPS promoted inflammatory reaction of
TNF-a production by RAW 264.7 cells, such a combination of HMGB1 with E.
coli-LPS showed very modest additive effects (about 20% increase). (Figures 3
and 5).

Among various concentrations (10, 100 and 1000 ng/ml) of three different
simulants tested (E. coli-LPS, Pg-LPS, and HMGB1), the pro-inflammatory effect
of HMGB1 or Pg-LPS in induction of TNF-a production by RAW264.7
macrophages were significantly lower than that mediated by E. coli-LPS. More
specifically, compared to E. coli-LPS that induced prominently elevated TNF-a
production by RAW264.7-macrophages (4000 – 6000 pg/ml), Pg-LPS as well as
HMGB1 displayed significantly lower levels of TNF-a production (at most 1000
14

pg/ml). However, combination of HMGB1 with Pg-LPS, but not E. coli-LPS,
showed a remarkable synergistic pro-inflammatory effect on levels of TNF-a
release when added to cultures of RAW264.7- macrophages. (Figures 4 and 5).
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Figure 3: Inflammatory response determined by TNF-a production from
RAW264.7-macrophages stimulated with HMGB1, E. coli-LPS or HMGB1/E. coliLPS complex. E. coli-LPS alone induced prominently elevated TNF-a production,
while its complex in combination with HMGB1 showed very modest (about 20%)
increase of pro-inflammatory responses.
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Figure 4: Inflammatory response based on TNF-a production by RAW264.7macrophages following stimulation with HMGB1, Pg-LPS, or HMGB1/Pg-LPS
complex. HMGB1 produced higher additive effects in combination with Pg-LPS,
than with E. coli-LPS.
Although both combinations of E. coli-LPS and HMGB1 as well as Pg-LPS
and HMGB1 promoted the increased inflammatory reaction of TNF-a, the
magnitude of HMGB1-induced synergistic effects with Pg-LPS indicates that
HMGB1 can form a hyper inflammatory complex with Pg-LPS, but not E. coliLPS. The combination of HMGB1 with Pg-LPS induced remarkably stronger proinflammatory response than the response induced by HMGB1/E.coli-LPS
complex. Indeed, the combination between HMGB1 and E. coli-LPS showed very
modest additive effect (about 20%) compared to E. coli-LPS alone (Figure 5).
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Figure 5: Percentage of increased TNF-a production by the addition of HMGB1.
In comparison to Pg-LPS alone, at least 3-fold increase of TNF-a production was
observed following RAW 264.7-cell stimulation with HMGB1/Pg-LPS complex
(synergistic effect). Such synergistic effect found in HMGB1/Pg-LPS complex was
not detected between E. coli-LPS and HMGB1 that showed 10-40% increase
(additive effect).
Release of IL-6 by RAW 264.7 macrophages following the stimulation with
HMGB1/E. coli-LPS or HMGB1/Pg-LPS complexes, as well as with the individual
component was evaluated (Figure 6). RAW 264.7 cells failed to produce any
detectable level of IL-6 or produced considerably minimal amounts of IL-6 in
response to stimulation with HMGB1 alone, P. gingivalis-LPS alone or preformed
HMGB1/Pg-LPS complex. E. coli-LPS alone and its combination with HMGB1
induced prominently elevated IL-6 production by macrophages. However, unlike
17

TNF-a, no additive effect by HMGB1 on E. coli-LPS-induced IL-6 production.
More specifically, contrast to the additive effects observed between HMGB1 and
E. coli-LPS on TNF-a production by RAW264.7 cells, the application of
preformed HMGB1 and E. coli-LPS displayed comparable IL-6 production (in
other words, no significant difference) by RAW 264.7 macrophages.
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Figure 6: IL-6 production by RAW264.7-macrophages in response to stimulation
with E. coli-LPS or Pg-LPS in the presence or absence of HMGB1. Stimulation with
HMGB1-Pg-LPS complex and with the single component of HMGB1 or Pg-LPS
failed to induce IL-6 production in macrophages. E. coli-LPS alone and in
combination with HMGB1 induced prominently elevated IL-6 production.
However, the stimulation of RAW264.7 cells with HMGB1/E.-coli LPS complexes
did not affect the IL-6 release induced by stimulation with E. coli-LPS alone.
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3.2.

MONITORING OF MACROPHAGES PROLIFERATION: WST ASSAY
To examine whether any of test compound(s) applied by itself or in

combination can affect the proliferation of macrophages, WST assay was
employed. After incubation of RAW264.7 cells in a 96 well plate with test
compounds (LPS or HMGB1) for 24 hours, a cell proliferation reagent WST-1
was added to the culture plates and incubated at 37°C for 2 hours. Following
incubation, the developed color in each well of the 96-well plate was measured.
The absorbance of developed color from WST-1-reacted macrophage cells is
proportional to the levels of viability and proliferation of the cells in response to
stimulation with E. coli-LPS and Pg-LPS with or without HMGB1 and to HMGB1
alone. Results revealed that the preformed complex of HMGB1 in combination
with Pg-LPS was the only group able to significantly upregulate the proliferation
of RAW264.7 macrophages. HMGB1 alone, E. coli-LPS alone or the preformed
complex of the combination between E coli-LPS and HMGB1 did not affect the
proliferation of macrophages, suggesting that HMGB1 combined with Pg-LPS
elicits a unique to upregulate the proliferation of macrophages (Figure 7).
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Figure 7: Determination of macrophage proliferation by the WST assay. The
combination of HMGB1 and Pg-LPS significantly upregulated macrophage
proliferation. Other tested groups did not affect the proliferation of macrophages.

3.3.

ANALYSIS OF MRNA EXPRESSIONS OF PAMP RECEPTORS: QPCR
To evaluate the expression pattern of PAMP receptors genes in RAW

264.7 macrophages, expression of mRNA for TLR2, TLR4 and RAGE was
analyzed using quantitative PCR. The relative ratio of the genes was compared
to an internal control (GAPDH). As shown in figures 8 to 10, the macrophages
used in this study expressed mRNAs for TLR2, TLR4 and RAGE, three of which
are reported as putative ligands for HMGB1. Contrast to E. coli-LPS that
significantly upregulated TLR4 mRNA expression, while suppressed both TLR2
and RAGE mRNAs, Pg-LPS or HMGB1 alone or in complex did not affect the
expression of any mRNA of the receptor tested. Results indicated that the
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additive effects between Pg-LPS and HMGB1 on TNF-𝛼 expression was not
mediated by modulation of PAMP receptors expressed on macrophages.
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Figure 8: Expression TLR2 mRNA in RAW 264.7-macrophages.
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Figure 9: Expression TLR4 mRNA in RAW 264.7-macrophages.
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Figure 10: Expression RAGE mRNA in RAW 264.7-macrophages.
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3.4.

EFFECTS OF CHEMICAL INHIBITORS FOR TLR2, TLR4 AND RAGE
In order to elucidate the mechanism underlying the pro-inflammatory

signaling pathways engaged in the TNF-a production by macrophages following
stimulation with HMGB1 alone, Pg-LPS alone or the pre-formed HMGB1/Pg-LPS
complex, chemical antagonists for TLRs and RAGE receptor were employed.
TNF-a levels produced by test components-stimulated macrophage culture that
also received the antagonists for TLR-2, TLR-4 or RAGE are shown in Figures 11
to 13. Results demonstrated that TNF-a secreted by macrophages stimulated
with Pg-LPS alone was inhibited only by TLR4-inhibitor, while the TNF-a
induction caused by HMGB1 alone was inhibited by both, TLR2-inhibitor and
TLR4-inhibitor. Meanwhile, the synergistic effect of HMGB1-Pg-LPS complex that
promoted TNF-a release was only inhibited by TLR4 inhibitor, but not TLR2 or
RAGE inhibitor. These results indicate that HMGB1/Pg-LPS complex acts on
TLR4, but not TLR2 or RAGE, which, in turn, upregulates the cell signal to
promote the TNF-a production.
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Figure 11: Effects of chemical inhibitors for TLR2, TLR4 and RAGE on TNF- 𝛼
production by macrophages stimulated with Pg-LPS. TLR2 inhibitor: CU CPT 22
(Sigma), TL4 Inhibitor: TAK 242 (Sigma), RAGE Inhibitor: FPS-ZM1 (Sigma)
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Figure 12: Effects of chemical inhibitors for TLR2, TLR4 and RAGE on TNF-𝛼
production by macrophages stimulated with HMGB1. TLR2 inhibitor: CU CPT 22
(Sigma), TL4 Inhibitor: TAK 242 (Sigma), RAGE Inhibitor: FPS-ZM1 (Sigma)
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Figure 13: Effects of chemical inhibitors for TLR2, TLR4 and RAGE on TNF- 𝛼
production by macrophages stimulated with Pg-LPS + HMGB1. TLR2 inhibitor: CU
CPT 22 (Sigma), TL4 Inhibitor: TAK 242 (Sigma), RAGE Inhibitor: FPS-ZM1
(Sigma)

3.5.

SUMMARY OF FINDINGS

Ø Combination of HMGB1 and Pg-LPS showed remarkable synergistic effects
on TNF-a production by macrophages. At least 3-fold increase of TNF-a
production was observed by HMGB1/Pg-LPS complex. However, such
synergistic effects were not detected between E. coli-LPS and HMGB1 which
showed a modest additive effect.
Ø Combination of HMGB1 and Pg-LPS also increased the proliferation of
macrophages, whereas of HMGB1 alone, Pg-LPS alone, E. coli-LPS alone, or
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the combination between E. coli-LPS and HMGB1 did not affect the
proliferation of macrophages.
Ø Macrophages used in this study expressed mRNAs for TLR2, TLR4 and
RAGE as putative ligands for HMGB1.
Ø Neither Pg-LPS or HMGB1 changed the expression levels of all three PAMP
receptors expressed by macrophages.
Ø According to the assay using PAMP-inhibitors, HMGB1 appeared to bind both
TLR2 and TLR4, while Pg-LPS acted on TLR4.
Ø The effect of HMGB1-Pg-LPS complex to promote TNF-a production was only
inhibited by TLR4 inhibitor, but not TLR2 or RAGE inhibitor, suggesting that
TLR4 play a key role in responding to HMGB1/Pg-LPS complex.
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CHAPTER 4: DISCUSSION
Results from this study demonstrated that extracellular HMGB1 can form a
hyper-inflammatory complex with Pg-LPS, while much lesser extent with E. coliLPS, which, via ligation with TLR4, upregulates TNF-a production from
macrophages. According to our results, at the same concentrations tested, the
activities of Pg-LPS and HMGB1 to induce TNF-a production from macrophages
were significantly lower than that of E. coli-LPS. Nonetheless, only Pg-LPS, but
not E. coli-LPS, showed the remarkable synergistic effect with HMGB1 on TNF-a
production by macrophages, suggesting that Pg-LPS possesses a distinct
property to induce pro-inflammatory response working in concert with HMGB1.
Furthermore, such a Pg-LPS/HMGB1-complex mediated promotion was only
found in production of TNF-a, but not IL-6, whereas Pg-LPS/HMGB1 complex
also upregulated the proliferation of macrophages. This study implicated that
pathogenic engagement of opportunistic pathogen, P. gingivalis, may be elicited
by locally elevated host-derived extracellular HMGB1 that can augment the
activity of Pg-LPS to stimulate TLR4 for induction of TNF-a production.

Current paradigm of periodontitis supports that dysbiosis of the oral
microbiome may play a crucial pathologic role in the onset and progression of
this disease. It is thought that small number of key bacteria in the community
drives the conversion of the healthy microbiome to dysbiosis state.20 The
emerging theory of “Keystone-Pathogen Hypothesis”21 proposes that certain low-
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abundance opportunistic pathogens, represented by P. gingivalis, can cause
dysbiosis by disrupting the host immune system and misshaping the microbiota
in periodontal tissue. Although a mouse model of P. gingivalis induced
periodontitis demonstrated that complement component 3 (C3) is associated with
the periodontal pathogenesis that augments the level of inflammation,22 the
precise molecular mechanism accounting for the P. gingivalis-mediated
upregulation of proinflammatory response in human patients remains elusive. To
this end, we propose that HMGB1/Pg-LPS complex may account for the
dysbiosis caused in periodontal tissue with periodontitis. Accumulated lines of
evidence support that inflammation is not induced by commensal Gram-negative
bacteria that colonize in the mucosal tissue of host due to the mechanism of
“endotoxin tolerance”.23 In the tissue culture system, common LPS, represented
by E. coli LPS, mitigates the pro-inflammatory response by host immune cells to
the secondary exposure to the same LPS, illustrating the state of “endotoxin
tolerance” in the in vitro context. However, it is reported that, Pg-LPS-exposed
host cells do not render to the state of endotoxin tolerance,24,25 suggesting that
unique structure of Pg-LPS14 also functions differently from the common LPS.
Based on these lines of evidence and the results obtained from this study, it is
theorized that locally released extracellular HMGB1 is engaged in pathogenic
conversion of Pg-LPS in the periodontal tissue where abundantly available
common LPS does not induce inflammation due to the endotoxin tolerance.
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While it was reported that HMGB1 can generate a hyper-pro-inflammatory
complex with E. coli-LPS that increases production of pro-inflammatory
cytokines, including TNF-a, IL-6 and IL-8,6,19 our experimental model using
RAW264.7 cells could not reproduce aforementioned results. Although HMGB1
by itself is weak in induction of inflammatory response, its interaction with TLRs26
or RAGE27 promotes the production of cytokines and other inflammatory
molecules from innate immune cells. As noted in the introduction, HMGB1 also
binds to DNA and LPS.28 Recent studies identified other pro-inflammatory
mediators, such as, thrombospondin, TREM-1, CD24, and CXCL12, can also
work in concert with HMGB1 to upregulate inflammatory responses.28,29
Furthermore, three isoforms of HMGB1 were reported including 1) disulfide
HMGB1 that can induce cytokine production via ligation with TLR4, 2) fully
reduced HMGB1 that upregulate CXCL12-mediated chemotaxis by legation with
CXCR4, and 3) oxidized HMGB1 which is inactive in activating either TLR or
CXCR4.30 Therefore, the reason why E. coli-LPS/HMGB1 complex did not show
the synergistic effects may be attributed to the presence of other factor produce
by RAW264,.7 cells that may hinders the ligation with TLR4 or oxidation of
HMGB1 in the culture of RAW264.7 cells that attenuated the ligation of E. coliLPS/HMGB1 complex with its receptor.

Recent reports have pointed out that HMGB1 is released in the gingival
crevicular fluid of patients with periodontitis as well as peri-implant crevice fluid
(PICF) of patients with peri-implantitis.9,31-33 The high level of HMGB1 expression
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is found in the active sites of in GCF and PIFC in conjunction with increased
levels of several pivotal pro-inflammatory cytokines, including TNF-a, IL1-β, IL-6
and IL-8, suggesting that HMGB1 and these pro-inflammatory cytokines may
develop a positive feedback loop to promote inflammation in chronic periodontitis
and peri-implantitis.33 In vitro stimulation of gingival epithelial cells with TNF-a
and IL-1β increase their secretion of HMGB1.7,34 In the present study, since we
focused on the effects of HMGB1 on the productions of proinflammatory
cytokines from macrophages, the release of HMGB1 from those macrophages
was not monitored. It is very intriguing to know whether positive feedback loop to
promote inflammation can be elicited in the in vitro assay using RAW264.7 cells.

In the septic shock, level of HMGB1 increases later than the elevation of
TNF-a or IL-1β in the circulation, indicating the possible engagement of HMGB1
in the endotoxin-induced lethal damage of host.35,36 Indeed, in the mouse model
of Cecal Ligation Puncture (CLP) or LPS-induced septic shock, the lethality and
elevated production of proinflammatory cytokines in circulation is significantly
suppressed by Dabrafenib that can attenuate the extracellular release of
HMGB137 or by Glycyrrhizin, a direct HMGB1 antagonist.38 Anti-HMGB1
neutralizing antibody administered to the mice induced of periodontitis by
infection with P. gingivalis inhibits the local secretion of proinflammatory
cytokines as well as bone resorption.39 According to our results, chemical
antagonist for TLR4 (TAK-242) inhibited the Pg-LPS/HMGB1-complex induced
TNF-a production from macrophages. Thus, if our hypothesis is proven to be true
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by future experiments using an animal model of periodontitis, it is expected that
at least one of the above listed inhibitors for HMGB1 (Dabrafenib, Glycyrrhizin,
xHMGB1-antibody or TAK-242) would show the clinical potency in the prevention
and amelioration of periodontitis associated with P. gingivalis. Since thus far
there is no small molecule-based drug is available for treatment of periodontitis,
and the treatment of periodontitis is relay on the invasive procedures, the results
obtained from current study may lead to the development of paradigm-shifting
non-invasive therapeutic approach for periodontitis.

4.1 STUDY LIMITATIONS AND FUTURE STUDIES CONSIDERATIONS
We must be cautious not to rule out the possibility of the endogenous HMGB1
being released from RAW264.7 cells, which in turn could have promoted the
cytokine productions directly without formation of complexes with other molecules.
To test whether HMGB1 is released from RAW264.7 cells, future studies could add
to their assessments the level of HMGB1 released into the culture supernatant
following RAW264.7 cells stimulation with P. gingivalis-LPS or E. coli-LPS
monitored using HMGB1 ELISA.

There is a possibility that the recombinant HMGB1 may not possess the
biological property of naturally available HMGB1, which, in turn, impairs the
function to form complex with bacterial LPS. A lack of biological activity of
recombinant HMGB1 may be caused by misfolding of recombinant HMGB1 during
the synthesis using E. coli expression system. It is not clear, among the three
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reported forms of HMGB1, i.e., 1) disulfide HMGB1, 2) fully reduced HMGB1, and
3) oxidized HMGB1,30 which form of HMGB1 is released in the inflamed tissue with
periodontitis. Furthermore, the misfolding of recombinant HMGB1 could be
detected by the unexpected outcome, i.e., the mixture of E. coli LPS and
recombinant HMGB1 does not promote the inflammatory response by RAW264.7
cells. In this case, future studies should consider purify the endogenous HMGB1
from the blood of healthy blood donor using anti-HMGB1 affinity purification
column. Then, the effects of purified authentic HMGB1 on P. gingivalis LPS could
be compared by the macrophage responses from both recombinant and
endogenous HMGB1 complexes.

The in vitro nature of this study might not reflect the physiological context of
patient with periodontitis. However, the range of pro-inflammatory cytokine
productions in response to stimulation with HMGB1-LPS should vary extensively
among human individuals, while intra-individual differences can also be expected.
For example, it is well established that the progression of periodontitis occurs in a
site-specific manner in the same patient. To address this issue, the level of
HMGB1/Pg LPS complex in patients gingival crevicular fluid (GCF) sampled from
different teeth could be assessed in future studies, along with levels of P. gingivalis
and pro-inflammatory cytokines.
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CHAPTER 5: CONCLUSIONS
High mobility group box protein 1 (HMGB1) is a nuclear protein that can be
released from host cells during infection or sterile injury, where it acts as a typical
alarmin exerting proinflammatory effects either by itself or through interaction with
endogenous or exogenous factors.40,41 Extracellularly released HMGB1 has the
property to bind to not only DNA, but also pathogenic molecules, such as LPS,
forming immune complexes that can trigger pro-inflammatory responses in a
synergistic way and have been is implicated in the pathogenesis of many immune
and inflammatory diseases.42-44

This study demonstrated that HMGB1 can make a hyper inflammatory
complex with Pg-LPS, but not E. coli-LPS, which in turn activates TLR4 and
upregulates the production of TNF-a from macrophages. In addition to HMGB1
signaling activity to promote cytokine release, the combination of HMGB1 and PgLPS displayed the ability to increase the proliferation of macrophages. These
results indicate that locally released HMGB1 may up-regulate the pathogenic
engagement of keystone pathogen, P. gingivalis, in periodontitis.

Furthermore, the enhanced TNF-a production from macrophages induced
by HMGB1 complex with Pg-LPS was inhibited by specific chemical antagonist for
TLR4 (TAK 242). This finding suggests that the observed effects of HMGB1 and
Pg-LPS induction of hyper-proinflammatory responses may be mediated through
the reciprocal receptors of the HMGB1-partner molecules. Consequently, this
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mechanism may lead to the development of a potential therapeutic approach to
inhibit the disease progression of P. gingivalis-associated periodontitis.

Since periodontitis not only deteriorates the patient’s quality of life, but also
increases the risk for chronic systemic diseases,45 there is a strong need for
developing novel preventive and therapeutic approaches for this disease.
Therefore, findings from the present study were paramount in the understanding
of basic pathophysiology of HMGB1 as a pro-inflammatory promoter, as well as its
role and mechanisms in the context of periodontitis. Moreover, the assessment
and validation of HMGB1 receptors and inhibitory signaling molecules will bring us
closer to their clinical application for designing a novel HMGB1-targeted
therapeutic approach.
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